Abstract
The cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progression, and are involved in uncontrolled cell proliferation—a hallmark of cancer. This suggests that small molecular inhibitors of CDKs might be attractive as prospective antitumor agents. To explore the relationship between the structures of substituted isoquinoline-1,3-(2H,4H)-diones and their inhibition of CDK4, 3D-QSAR studies were performed on a dataset of 48 compounds. The bioactive conformation of template compound 34 was obtained by performing molecular docking into the ATP binding site of the homology model of CDK4 and ranking by highest consensus score, which was then used to build and align the rest of the molecules in the series. The constructed comparative molecular similarity indices analysis (CoMSIA) produces significantly better results than comparative molecular field analysis (CoMFA), with \( r_{\text{cv}}^2 \) = 0.707 and r 2 = 0.988. The contours analysis provides useful information about the structural requirements for substituted isoquinoline-1,3-(2H,4H)-diones for CDK4 inhibitory activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Harper JW, Adams PD (2001) Cyclin-dependent kinases. Chem Rev 101:2511–2526
Massague J (2004) G1 cell-cycle control and cancer. Nature 432:298–306
Knockaert M, Greengard P, Meijer L (2002) Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23:417–425
Yu Q, Sicinska E, Geng Y et al (2006) Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9:23–32
Meijer L, Borgne A, Mulner O et al (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527–536
Senderowicz AM, Headlee D, Stinson SF et al (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986–2999
Fuse E, Kuwabara T, Sparreboom A et al (2005) Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 45:394–403
Fry DW, Harvey PJ, Keller PR et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427–1438
Misra RN, Xiao HY, Kim KS et al (2004) N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2.N-[5-[[[5-(1, 1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47:1719–1728
Wang S, Meades C, Wood G et al (2004) 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem 47:1662–1675
Singh SK, Dessalew N, Bharatam PV (2006) 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors. Eur J Med Chem 41:1310–1319
Dessalew N, Singh SK (2008) 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors. Med Chem 4:313–321
Dessalew N, Bharatam PV (2007) 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity. Eur J Med Chem 42:1014–1027
Mascarenhas NM, Ghoshal N (2008) Combined ligand and structure based approaches for narrowing on the essential physicochemical characteristics for CDK4 inhibition. J Chem Inf Model 48:1325–1336
Caballero J, Fernández M, González NF (2008) Structural requirements of pyrido2, 3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses. Bioorg Med Chem 16:6103–6115
Tsou HR, Otteng M, Tran T (2008) 4-(Phenylaminomethylene) isoquinoline-1, 3(2H, 4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4). J Med Chem 51:3507–3525
Sybyl ver.6.9, TRIPOS, St Louis, http://tripos.com
Jones G, Willett P, Glen RC et al (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727–748
Wold S, Albano C, Dunn WJ III et al (1984) In: Kowalski BR (ed) Chemometrics-mathematics and statistics in chemistry. Riedel, Dordrecht, pp 17–95
Stahle L, Wold S (1987) Partial least squares analysis with cross-validation for the two-class problem: a. Monte Carlo study. J Chemom 1:185–196
Cramer RD, Bunce JD, Patterson DE (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 7:18–25
Podlogar BL, Ferguson DM (2000) QSAR and CoMFA: a perspective on the practical application to drug discovery. Drug Des Discov 17:4–12
Honma T, Hayashi K, Aoyama T (2001) Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem 44:4615–4627
Protein Data Bank http://www.rcsb.org/pdb/explore.do?structureId=1PKD
Accelrys Inc. http://www.accelrys.com.
Kontoyianni M, McClellan LM, Sokol GS (2004) Evaluation of docking performance: comparative data on docking algorithms. J Med Chem 47:558–565
Mascarenhas NM, Ghoshal N (2008) An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation-a case study with CDK2/CyclinA. Eur J Med Chem 43:2807–2818
Schulz GE, Schirmer RH (1974) Topological comparison of adenyl kinase with other proteins. Nature 250:142–144
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lu, XY., Chen, YD., Sun, Ny. et al. Molecular-docking-guided 3D-QSAR studies of substituted isoquinoline-1,3-(2H,4H)-diones as cyclin-dependent kinase 4 (CDK4) inhibitors. J Mol Model 16, 163–173 (2010). https://doi.org/10.1007/s00894-009-0529-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00894-009-0529-7